3 insiders bought €1.8M of shares over the last 90 days, the latest filed 06 Aug 2026.
Alzchem Group AG belongs to the Chemicals & Materials sector. Filings by its managers are published through BaFin. The last twelve months, up to 18 October 2026, brought 7 filings signed by 4 insiders.
Both sides are active: 6 purchases worth €1.9M and 1 sale worth €37.6M, from 4 insiders and 1 insider respectively. Sales outweigh purchases by €35.7M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 3 senior executives. One trade stands out by size: a sale of €37.6M from four two na GmbH, disclosed on 26 January 2026.
Across the 287 companies tracked on its exchange, the median is 5 filings; at 7 filings, this issuer sits above that mark. Over the whole record (from 2025), the tally stands at 6 purchases and 2 sales.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 6 August 2026, which is 72 days ago. The median gap between a trade and its publication by BaFin is 4 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Other companies in the same sector with recent insider buying flagged by our signals: Culp Inc. Every figure here comes from the filings published by BaFin and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Alzchem Group AG Strong Buy (bullish), based on 8 analysts. Average price target: €205.81.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
8 of 8 declarations
Alzchem Group AG is a German specialty chemicals company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in the regulated market (Prime Standard) in Germany. Headquartered in Trostberg, Bavaria, the company is embedded in the long-established Bavarian Chemical Triangle and operates four production sites in Germany, an additional plant in Sweden, and sales operations in the United States, China, and the United Kingdom. This footprint reflects a vertically integrated, export-oriented industrial model focused on technically demanding niches rather than commodity-scale volumes.
The group’s roots lie in decades of industrial development around nitrogen chemistry and chemical intermediates. Today, Alzchem reports through three business segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The main value-creation engine is the Specialty Chemicals segment, which includes well-known brands and products such as Creapure®, Creamino®, Bioselect®, DYHARD®, Dormex®, and Nitroguanidine. Its offering spans human and animal nutrition, PCR test precursors, pharmaceutical raw materials, agriculture-related solutions, metallurgy, infrastructure applications, and selected industrial and defense uses. The Basics & Intermediates segment supplies chemical intermediates for internal use and external customers, reinforcing the group’s industrial integration.
Alzchem’s competitive position is built on three pillars: a strong focus on niche specialty markets, a “Verbund production” setup that reduces dependence on external suppliers, and close geographic proximity among its Bavarian plants, which supports manufacturing synergies, R&D efficiency, and operational flexibility. In a still-challenging European chemical environment, this positioning has allowed the company to preserve and improve profitability. For 2024, Alzchem reported external sales of EUR 554.2 million and EBITDA of EUR 105.3 million. For 2025, the company said it delivered another record year, underscoring the resilience of its business model.
Recent milestones include the strong earnings progression in 2024, supported by higher-margin specialty chemicals, as well as Alzchem’s inclusion in the SDAX on October 2, 2024. Into 2025/2026, the group also announced a growth investment program, pointing to continued confidence in its long-term niche-market strategy. For French-speaking investors, Alzchem stands out as a mid-cap industrial specialty chemicals name with a solid German manufacturing base and global commercial reach.
Purchases our model currently ranks for the recommendations list.
All recommendations